Christine Mona

Assistant Adjunct Professor, Molecular and Medical Pharmacology, University of California Los Angeles

Publications

  1. Beekman F, Czernin J, Mona C. Inventing His Own Career Path: Freek Beekman Talks with Johannes Czernin and Christine Mona About Success in Academia and Industry.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024.
  2. Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, Dry SM, Masri MG, Crompton JG, Benz MR, Czernin J, Eilber FC, Graeber TG, Calais J, Federman NC. Fibroblast Activation Protein Expression in Sarcomas.. Sarcoma, 2023.
  3. Hotta M, Mona CE, Crompton JG, Armstrong WR, Gafita A, Nelson SD, Eilber FC, Dawson DW, Calais J, Benz MR. FAPI PET Signal in Hibernoma Reflects FAP Expression in Tumor Vasculature Cells.. Clinical nuclear medicine, 2023.
  4. Lückerath K, Trajkovic-Arsic M, Mona CE. Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment.. PET clinics, 2023.
  5. Le TM, Lee HR, Abt ER, Rashid K, Creech AL, Liang K, Cui J, Cho A, Wei L, Labora A, Chan C, Sanchez E, Kriti K, Karin D, Li L, Wu N, Mona C, Carlucci G, Hugo W, Wu TT, Donahue TR, Czernin J, Radu CG. 18F-FDG PET Visualizes Systemic STING Agonist-Induced Lymphocyte Activation in Preclinical Models.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
  6. Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K, Razmaria A, Riahi R, Slavik R, Girgis MD, Carlucci G, Kelly KA, French SW, Czernin J, Dawson DW, Calais J. Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
  7. Vivancos M, Fanelli R, Besserer-Offroy É, Beaulieu S, Chartier M, Resua-Rojas M, Mona CE, Previti S, Rémond E, Longpré JM, Cavelier F, Sarret P. Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia.. Behavioural brain research, 2021.
  8. Calais J, Mona CE. Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Point-An Important Diagnostic, Phenotypic, and Biomarker Role.. AJR. American journal of roentgenology, 2020.
  9. Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais J, Eiber M, Dahlbom M, Czernin J, Radu CG, Lückerath K, Slavik R. Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
  10. Sonni I, Lee-Felker S, Memarzadeh S, Quinn MM, Mona CE, Lückerath K, Czernin J, Calais J. 68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation.. European journal of nuclear medicine and molecular imaging, 2020.
  11. Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, Lückerath K. Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
  12. Brouillette RL, Besserer-Offroy É, Mona CE, Chartier M, Lavenus S, Sousbie M, Belleville K, Longpré JM, Marsault É, Grandbois M, Sarret P. Cell-penetrating pepducins targeting the neurotensin receptor type 1 relieve pain.. Pharmacological research, 2020.
  13. Sun DL, Poddar S, Pan RD, Rosser EW, Abt ER, Van Valkenburgh J, Le TM, Lok V, Hernandez SP, Song J, Li J, Turlik A, Chen X, Cheng CA, Chen W, Mona CE, Stuparu AD, Vergnes L, Reue K, Damoiseaux R, Zink JI, Czernin J, Donahue TR, Houk KN, Jung ME, Radu CG. Isoquinoline thiosemicarbazone displays potent anticancer activity with in vivo efficacy against aggressive leukemias.. RSC medicinal chemistry, 2020.
  14. Stuparu AD, Meyer CAL, Evans-Axelsson SL, Lückerath K, Wei LH, Kim W, Poddar S, Mona CE, Dahlbom M, Girgis MD, Radu CG, Czernin J, Slavik R. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study.. Theranostics, 2020.
  15. Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, Stuparu AD, Cheng C, Dawson DW, Radu CG, Czernin J, Lueckerath K. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020.
  16. Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, Czernin J, Haberkorn U, Calais J. Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
  17. Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.. EJNMMI research, 2018.
  18. Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP. Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018.
  19. Mona CE, Besserer-Offroy É, Cabana J, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E. Design, synthesis, and biological evaluation of CXCR4 ligands.. Organic & biomolecular chemistry, 2016.
  20. Mona CE, Besserer-Offroy É, Cabana J, Lefrançois M, Boulais PE, Lefebvre MR, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E. Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.. Journal of medicinal chemistry, 2016.